The ICMIC(gStanford has matured from a P20 initially funded in 2000, with subsequent funding of the ICMIC PSO in 2004, to a multidisciplinary program with the expertise and infrastructure to support the growing field of multimodality molecular imaging. Dr Gambhir, the ICMIC PI, has made a conscious effort to merge his interests in radiology and molecular pharmacology to focus on the rapidly emerging field of molecular imaging. Eariier on, Dr. Gambhir was a key contributor to the UCLA-ICMIC where his lab very competently provided the ideal link between basic cancer biologists and biomedical imaging scientists. Dr. Gambhir then moved to Stanford with his lab of 20 students/postdocs in July 2003. ICMIC Co-PI, Dr. Contag, has spent a significant portion of his career focused on small animal bioluminescence optical imaging and has helped to make this technology widely available on the Stanford Campus and beyond. Together Drs. Gambhir and Contag provide an enormous breadth spanning from basic science, to pre-clinical imaging, to clinical applications of molecular imaging. Additionally, they both also have a primary emphasis on the study of cancer, and are both committed to clinical translation of molecular imaging.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA114747-08
Application #
8382022
Study Section
Special Emphasis Panel (ZCA1-SRLB-9)
Project Start
Project End
Budget Start
2012-09-01
Budget End
2013-08-31
Support Year
8
Fiscal Year
2012
Total Cost
$49,913
Indirect Cost
Name
Stanford University
Department
Type
DUNS #
009214214
City
Stanford
State
CA
Country
United States
Zip Code
94305
Natarajan, Arutselvan; Patel, Chirag B; Ramakrishnan, Sindhuja et al. (2018) A Novel Engineered Small Protein for Positron Emission Tomography Imaging of Human Programmed Death Ligand-1 : Validation in Mouse Models and Human Cancer Tissues. Clin Cancer Res :
Sun, Yao; Zeng, Xiaodong; Xiao, Yuling et al. (2018) Novel dual-function near-infrared II fluorescence and PET probe for tumor delineation and image-guided surgery. Chem Sci 9:2092-2097
Natarajan, Arutselvan; Patel, Chirag B; Habte, Frezghi et al. (2018) Dosimetry Prediction for Clinical Translation of 64Cu-Pembrolizumab ImmunoPET Targeting Human PD-1 Expression. Sci Rep 8:633
Habte, Frezghi; Natarajan, Arutselvan; Paik, David S et al. (2018) Quantification of Cerenkov Luminescence Imaging (CLI) Comparable With 3-D PET Standard Measurements. Mol Imaging 17:1536012118788637
Hori, Sharon Seiko; Lutz, Amelie M; Paulmurugan, Ramasamy et al. (2017) A Model-Based Personalized Cancer Screening Strategy for Detecting Early-Stage Tumors Using Blood-Borne Biomarkers. Cancer Res 77:2570-2584
Ronald, John A; Kim, Byung-Su; Gowrishankar, Gayatri et al. (2017) A PET Imaging Strategy to Visualize Activated T Cells in Acute Graft-versus-Host Disease Elicited by Allogenic Hematopoietic Cell Transplant. Cancer Res 77:2893-2902
Jiang, Lei; Tu, Yingfeng; Hu, Xiang et al. (2017) Pilot Study of 64Cu(I) for PET Imaging of Melanoma. Sci Rep 7:2574
Keu, Khun Visith; Witney, Timothy H; Yaghoubi, Shahriar et al. (2017) Reporter gene imaging of targeted T cell immunotherapy in recurrent glioma. Sci Transl Med 9:
Hong, Su Hyun; Sun, Yao; Tang, Chu et al. (2017) Chelator-Free and Biocompatible Melanin Nanoplatform with Facile-Loading Gadolinium and Copper-64 for Bioimaging. Bioconjug Chem 28:1925-1930
Shen, Bin; Behera, Deepak; James, Michelle L et al. (2017) Visualizing Nerve Injury in a Neuropathic Pain Model with [18F]FTC-146 PET/MRI. Theranostics 7:2794-2805

Showing the most recent 10 out of 424 publications